21 November 2024
Latham & Watkins Advises on Gilead Sciences’ US$3.5 Billion Senior Unsecured Notes Offering
Advising firms
Deal team
19 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Greg Rodgers Lead | Latham & Watkins LLP | Partner | corporate | New York/Los Angeles |
| Chuck Cassidy | Latham & Watkins LLP | Partner | corporate | Washington, D.C./New York |
| Karysa Norris | Latham & Watkins LLP | Associate | corporate | Not stated |
| Steve Hess | Latham & Watkins LLP | Associate | corporate | Not stated |
| Bora Bozkurt | Latham & Watkins LLP | Partner | tax | New York |
| Betty Pang | Latham & Watkins LLP | Partner | healthcare | Bay Area |
| Christopher Hazuka | Latham & Watkins LLP | Partner | intellectual property | San Diego/Bay Area |
| Robert Yeh | Latham & Watkins LLP | Associate | intellectual property | Not stated |
| Patrick Chew | Latham & Watkins LLP | Associate | intellectual property | Not stated |
| Heather Deixler | Latham & Watkins LLP | Not stated | data privacy | Not stated |
| Kiara Vaughn | Latham & Watkins LLP | Associate | data privacy | Not stated |
| Ben Haas | Latham & Watkins LLP | Partner | FDA regulatory | Washington, D.C. |
| Chad Jennings | Latham & Watkins LLP | Counsel | FDA regulatory | Washington, D.C. |
| Meryl Bartlett | Latham & Watkins LLP | Associate | FDA regulatory | Not stated |
| Ruchi Gill | Latham & Watkins LLP | Counsel | sanctions | Washington, D.C. |
| Elliot Hecht | Latham & Watkins LLP | Associate | sanctions | Not stated |
| Eveline Van Keymeulen | Latham & Watkins LLP | Partner | EU/UK regulatory | Paris/Brussels |
| Jeanne Fabre | Latham & Watkins LLP | Associate | EU/UK regulatory | Not stated |
| Kevin Chambers | Latham & Watkins LLP | Partner | anti-corruption | Washington, D.C. |
Stated terms
- Stated value
- USD 3.50bn (US$3.5 billion)
- What the figure measures
- Issue size
- Client
- Latham & Watkins LLPUnderwriters
- Counterparties
- Gilead Sciences, Inc. (Issuer)